Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Successful Toxicity Reduction in Ma-Spore ALL 2010 in Standard/Intermediate Risk Childhood ALL: Replacing Cytarabine/Doxorubicin with More Vincristine and L-Asparaginase during Consolidation and Delayed Intensification

Bernice Oh, MBBS, MRCP, Shawn Lee, MD, Zelia Seeto, Germaine Liew, Bsc, Edwynn Chiew, MBBS, Zhi Wei Chen, Bsc, Yiong Huak Chan, PhD, Jing Jia Eng, Bsc, Koon Mian Foo, Bsc, Ching Mei Joyce Lam, MD, Ah Moy Tan, MD, Allen Eng Juh Yeoh, MD

Blood (2019) 134 (Supplement_1): 1307.

https://doi.org/10.1182/blood-2019-122098

Published: 2019

Journal Articles

Optimal International Normalized Ratio Range for Asian Patients on Anticoagulation Therapy

Lai Heng Lee, MBBS,FRCP, Ming Chai Kong, Isabelle Teo, Shun Wei Lim, Jin Shing Hon, Kelly Bee Ling Chng, Sing Lin Tee, Elicia Purnata, Clifton You Xuan Liew, Xin Hui Loh, Cui Mei Fong, Nirmali Ruth Sivapragasam, Yiong Huak Chan, Jiang Ming Fam, Heng Joo Ng, Marcus Eng Hock Ong, David Bruce Matchar

Blood (2017) 130 (Supplement 1): 3719.

https://doi.org/10.1182/blood.V130.Suppl_1.3719.3719

Published: 2017

Journal Articles

Bortezomib (BTZ) and Panobinostat (PAN) Combination Is Effective in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) or NK/T-Cell Lymphoma (NKL) and Maintenance Treatment May Be Essential for Sustained Response

Daryl Tan, MD, William YK Hwang, MBBS, FRCP, FAMS, Colin Phipps Diong, Wee Lee Goh, BSC, Lionel K.Y See, BSc, Yiong Huak Chan, PHD, Soon Thye Lim, MRCP MBBS, Soo Chin Ng, MBBS MRCP, S Fadilah, MBBS, Soo-Yong Tan, MBBS, FRCPath, DPhil, Won Seog Kim, MD, Yeow Tee Goh, MD

Blood (2012) 120 (21): 3669.

https://doi.org/10.1182/blood.V120.21.3669.3669

Published: 2012

Journal Articles

Single IGH/TCR MRD Marker Is More Informative and Cost-Effective in Risk-Stratified Therapy for Childhood ALL: Prospective Treatment Trial Results from the Malaysia-Singapore (Ma-Spore) ALL 2003 Study

Allen Eng Juh Yeoh, MD, Hany Ariffin, MD, Ah Moy Tan, MD, Thi Thu Ha Truong, BSc, Hai Peng Lin, MD, Yiong Huak Chan, PhD, Shirley Kow Yin Kham, BSc, Thuan Chong Quah, MD

Blood (2008) 112 (11): 2551.

https://doi.org/10.1182/blood.V112.11.2551.2551

Published: 2008

Journal Articles

MDR1 C3435T Polymorphism Is Highly Correlated with Early Response to Therapy and Outcome in Childhood Acute Lymphoblastic Leukaemia: Malaysia-Singapore 2003 ALL Study.

Shirley Kow Yin Kham, BSc, Hany Ariffin, MD, Yiong Huak Chan, PhD, Thuan Chong Quah, MD, Allen Eng Juh Yeoh, MD

Blood (2007) 110 (11): 226.

https://doi.org/10.1182/blood.V110.11.226.226

Published: 2007

Journal Articles

Methylenetetrahydrofolate Reductase (MTHFR) C677T Polymorphism Decreases Risk of Childhood Acute Lymphoblastic Leukemia (ALL): A Study of the Chinese and Malay Population.

Shirley Kow Yin Kham, BSc, Toon Chai Foo, Ariffin Hany, MD, Yiong Huak Chan, PhD, Hai Peng Lin, MD, Thuan Chong Quah, MD, Allen Eng Juh Yeoh, MD

Blood (2005) 106 (11): 1459.

https://doi.org/10.1182/blood.V106.11.1459.1459

Published: 2005

NARROW

Successful Toxicity Reduction in Ma-Spore ALL 2010 in Standard/Intermediate Risk Childhood ALL: Replacing Cytarabine/Doxorubicin with More Vincristine and L-Asparaginase during Consolidation and Delayed Intensification

Optimal International Normalized Ratio Range for Asian Patients on Anticoagulation Therapy

Bortezomib (BTZ) and Panobinostat (PAN) Combination Is Effective in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) or NK/T-Cell Lymphoma (NKL) and Maintenance Treatment May Be Essential for Sustained Response

Single IGH/TCR MRD Marker Is More Informative and Cost-Effective in Risk-Stratified Therapy for Childhood ALL: Prospective Treatment Trial Results from the Malaysia-Singapore (Ma-Spore) ALL 2003 Study

MDR1 C3435T Polymorphism Is Highly Correlated with Early Response to Therapy and Outcome in Childhood Acute Lymphoblastic Leukaemia: Malaysia-Singapore 2003 ALL Study.

Methylenetetrahydrofolate Reductase (MTHFR) C677T Polymorphism Decreases Risk of Childhood Acute Lymphoblastic Leukemia (ALL): A Study of the Chinese and Malay Population.

Email alerts

ASH Publications

American Society of Hematology

Successful Toxicity Reduction in Ma-Spore ALL 2010 in Standard/Intermediate Risk Childhood ALL: Replacing Cytarabine/Doxorubicin with More Vincristine and L-Asparaginase during Consolidation and Delayed Intensification

Optimal International Normalized Ratio Range for Asian Patients on Anticoagulation Therapy

Bortezomib (BTZ) and Panobinostat (PAN) Combination Is Effective in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) or NK/T-Cell Lymphoma (NKL) and Maintenance Treatment May Be Essential for Sustained Response

Single IGH/TCR MRD Marker Is More Informative and Cost-Effective in Risk-Stratified Therapy for Childhood ALL: Prospective Treatment Trial Results from the Malaysia-Singapore (Ma-Spore) ALL 2003 Study

MDR1 C3435T Polymorphism Is Highly Correlated with Early Response to Therapy and Outcome in Childhood Acute Lymphoblastic Leukaemia: Malaysia-Singapore 2003 ALL Study.

Methylenetetrahydrofolate Reductase (MTHFR) C677T Polymorphism Decreases Risk of Childhood Acute Lymphoblastic Leukemia (ALL): A Study of the Chinese and Malay Population.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only